Abstract: A lockable power module is locked in position within a battery compartment of an electronic flash unit by manually displacing a pair of locking members on the module outwardly therefrom to tightly grip the compartment walls.

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, 1-mercapto C.sub.2-7 alkyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or --C(C.sub.1-6 alkyl(NOH) or --C(C.sub.1-6 alkyl)NNH.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof; ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is C.sub.1-7 alkyl substituted by NR.sub.8 R.sub.9 where R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further heteroatom which is oxygen, sulphur or nitrogen substituted by R.sub.10 where R.sub.10 is hydrogen, C.sub.1-4 alkyl or benzyl, and optionally substituted by one or two C.sub.1-4 alkyl, C.sub.2-5 alkanoyl, C.sub.1-4 alkoxycarbonyl, aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups or by a benzyl group, cyano, phenyl or benzyl and wherein any phenyl or benzyl group is optionally substituted in the phenyl ring by one or two halo, CF.sub.3, C.sub.1-4 alkyl, C.sub.

Abstract: A storage stable anticalculus toothpaste comprising at least about 4%, by weight, based on the total weight of the toothpaste, of a water-soluble alkali metal tripolyphosphate, a phosphatase enzyme inhibitor consisting of a fluoride ion source in an amount sufficient to supply from about 25 ppm to about 3500 ppm of fluoride ion, a silica or plastics dental abrasive and an orally acceptable vehicle, the toothpaste having a pH of from about 8 to about 10.

Abstract: An oral hygiene composition in the form of a dentifrice or a mouthwash, comprising: (a) from 0.01 to 2% by weight of the composition of an antibacterial compound of formula (I): ##STR1## in which R.sup.1 is oxygen, sulphur or an alkylene group of from 1 to 6 carbon atoms, each of R.sub.2 to R.sub.6 and R.sup.2 ' to R.sup.6 ' is hydrogen, hydroxyl or halogen; (b) from 0 to 90% by weight of a dentally acceptable abrasive, (c) from 0.1% to 15% by weight of a dialkali or tetra-alkali metal pyrophosphate salt or a mixture thereof and (d) water.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is selected from C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-4 alkyl, COR.sub.8 where R.sub.8 is hydroxy, C.sub.1-6 alkoxy or NR.sub.9 R.sub.10 where R.sub.9 and R.sub.10 are independently hydrogen or C.sub.1-4 alkyl and CH.sub.2 OR.sub.11 and R.sub.11 is hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkanoyl;R.sub.5 is hydrogen, C.sub.1-6 alkyl or phenyl C.sub.1-4 alkyl;R.sub.6 is phenyl C.sub.1-7 alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho-nitro, meta- or para-methoxy, methyl or NR.sub.12 R.sub.13 wherein R.sub.12 and R.sub.13 are independently hydrogen or C.sub.1-6 alkyl or R.sub.12 and R.sub.13 together are C.sub.2-6 polymethylene or the phenyl moiety is 3,4-disubstituted by methylenedioxy or ethylenedioxy; andR.sub.7 is hydrogen or C.sub.

Abstract: This patent covers a chimney in prefabricated modular elements, normally but not exclusively to be built outside buildings.The flue stack consists of two modular prefabricated elements (A,B) to be assembled by progressive raising. The first element (A) is consisting of an outer covering pipe (1) usually having a square cross section, an intermediate pipe (2) usually having a circular cross section and an internal liner (4) usually having a circular cross section, all pipes being rectilinear and interconnected by stirrups, while the hollow space between outer (1) and intermediate pipe (2) is filled with insulating material (3). The second element (B) has normally a shorter length than the first and consists of an outer envelope (pipe) (1), an intermediate pipe (2), both rectilinear, while the internal pipe (4) has a bend or branch at its lower end for connection to the exhaust of the various users.

Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein Y is S or O;R is hydrogen or alkyl having from about 1 to about 4 carbon atoms;R.sup.1 is hydrogen, alkyl having from about 1 to about 4 carbon atoms, alkoxy having from about 1 to about 4 carbon atoms, halogen or trifluoromethyl;R.sup.2 is hydrogen or unsubstituted or substituted alkyl having from about 1 to about 4 carbon atoms; andR.sup.3 is hydrogen, alkyl having from about 1 to about 6 carbon atoms, cycloalkyl having from about 3 to about 6 carbon atoms, alkoxy having from about 1 to about 4 carbon atoms, aryloxy having from about 6 to about 10 carbon atoms, alkylthio having from about 1 to about 4 carbon atoms, hydroxyalkoxy having from about 1 to about 4 carbon atoms, or unsubstituted or substituted phenyl is useful to obtain inhibition of aldose reduction in animals, including humans.

Abstract: A purified fibrinolytically active degraded species of tissue-type plasminogen activator comprising a fibrinolytically intact B chain of native t-PA linked to kringle 2 as the only functionally and structurally intact domain of native t-PA A chain.

Abstract: A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen;R.sub.2 and R.sub.3 are both hydrogen or together represent a bond;R.sub.4 is hydrogen and R.sub.5 is hydrogen or R.sub.4 and R.sub.5 together represent an oxo group;R.sub.6 is phenyl C.sub.1-7 alkanoyl in which the phenyl moiety is optionally substituted by one or two of halogen, nitro, meta- or para-methoxy, methyl or NR.sub.8 R.sub.9 wherein R.sub.8 and R.sub.9 are independently hydrogen or C.sub.1-6 alkyl or R.sub.8 and R.sub.9 together are C.sub.2-6 polymethylene, or 3,4-disubstituted by methylenedioxy or ethylenedioxy; or C.sub.1-7 alkanoyl substituted by NR.sub.10 R.sub.11 where R.sub.10 and R.sub.11 are independently hydrogen or C.sub.1-4 alkyl or together are C.sub.3-7 polymethylene optionally containing a further heteroatom which is oxygen, sulphur or nitrogen substituted by R.sub.12 where R.sub.

Abstract: A low tack orthopedic splinting material which includes a substrate coated with a low tack water curable composition that has an isocyanate resin which has dissolved therein from 1 to 10% of a compound of the formula (VII): R.sup.1 --X--(OCH.sub.2 CH.sub.2).sub.n --O--CO--(NH).sub.m --R.sup.2 wherein R.sup.1 is alkyl of 1 to 14 carbon atoms, phenyl, phenyl substituted by alkyl of 1 to 12 carbon atoms or alkyl of 1 to 4 carbon atoms substituted by phenyl, R.sup.2 is alkyl of 1 to 14 carbon atoms, phenyl, phenyl substituted by alkyl of 1 to 12 carbon atoms or alkyl of 1 to 4 carbon atoms substituted by phenyl, n is 6 to 100, m is 0 or 1 and x is a bond or --(NH).sub.m --CO--.

Abstract: 9-(N'-substituted hydrazone) derivatives of certain erythromycin compounds are novel, antibacterially active compounds which can be prepared by treatment of the corresponding 9-imine derivative with an N'-substituted hydrazine.

Abstract: A secondary antibody capable of stabilizing the binding of a small molecule to its binding protein is described which secondary antibody is capable of binding said binding protein in the presence of an in the absence of the small molecule but is not capable of binding said small molecule in the absence of binding protein. Such antibodies may be obtained by forming a complex between a small molecule and its binding protein, using the complex to raise antibodies and selecting the antibodies. The antibodies may be used in competitive assays in which it is desired to improve the binding of a small molecule or labelled small molecule to its binding protein.

Abstract: The present invention provides a novel nootropic agent which is applicable to senile dementia, etc.As a nootropic agent, for example, TRH (Thyrotropin releasing hormone) is hitherto known but involves defects that TRH is rapidly decomposed in vivo and, in its nature, cannot be orally administered.The nootropic agent in accordance with the present invention comprises as a main ingredient the substance having the following chemical structure: ##STR1## wherein R represents a lower alkyl group. The effect on animals is remarkable and the toxicity is low. Therefore, the compounds of the present invention are expected to be utilized as drugs. When the society is considered to go toward advanced age, a great weight should be put on treatment of diseases in old age and medical significance of the present invention is extremely important.

Abstract: A degreasing or moisturizing composition contains silanized silica gel, a humectant such as glycerine, and an inert carrier. The composition is used to treat sebhorreic conditions without causing dry skin.

Abstract: Compounds of formula (I) and their salts and esters: ##STR1## wherein X is hydrogen or a group NHR.sup.1, wherein R.sup.1 is hydrogen or an amino protecting group, and R is optionally substituted C.sub.5-8 cycloalkyl or cycloalkenyl, are useful in the treatment of bacterial infections.

Abstract: A compound, or a solvate or salt thereof, of formula (I): ##STR1## in which: RCO is an acyl group in which the group R contains a substituted or unsubstituted carbocyclic aromatic or heterocyclic aromatic ring and R.sub.1 R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.4 -12 cycloalkylalkyl groups or together form a C.sub.2-8 branched or linear polymethylene or C.sub.2-6 alkenylene group optionally substituted with a hetero-atom;R.sub.3 is hydrogen, C.sub.1-6 alkyl, or phenyl, or R.sub.3 together with R.sub.1 forms a --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 --, group; R.sub.4 and R.sub.5, which may be the same or different and may be attached to the same or different carbon atoms of the isoquinoline nucleus, are each hydrogen, halogen, hydroxy, C.sub.1-6 alkyl, aryl, or R.sub.4 together with R.sub.5 form a --(CH.sub.2).sub.p -- group, where p is an integer of from 1 to 5 and one or more of the --(CH.sub.2)-- moieties is optionally substituted by a C.

Abstract: The present invention provides ganglioside-related compounds expressed by the following formula: ##STR1## (wherein R.sub.1 denotes a hydrogen atom or SiR.sub.3 R.sub.4 R.sub.5 (wherein R.sub.3 and R.sub.4 each denotes a methyl or phenyl group, and R.sub.5 denotes a tertiary butyl or dimethylphenylmethyl group), and R.sub.2 denotes a hydrogen atom, a trityl group, or ##STR2## (wherein M denotes an alkali metal atom)) and methods of producing the same. These ganglioside-related compounds are useful as markers for the early detection of cancer and in the immunotherapy for cancer.